Adaptive Biotechnologies
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage ent...
Latest News
6 days ago · globenewswire.com
Adaptive Biotechnologies to Participate in Upcoming Investor ConferencesSEATTLE, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), ), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences. Jefferies Global Healthcare Conference in London, UKPresentation on Wednesday, November 18, 2026, at 4:00 p.m.
6 days ago · zacks.com
Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run?Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
12 days ago · seekingalpha.com
Adaptive Biotechnologies Corporation (ADPT) Q3 2026 Earnings Call TranscriptAdaptive Biotechnologies Corporation (ADPT) Q3 2026 Earnings Call Transcript
12 days ago · zacks.com
Adaptive Biotechnologies (ADPT) Q3 Earnings and Revenues Top EstimatesAdaptive Biotechnologies (ADPT) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.15 per share a year ago.
12 days ago · zacks.com
Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesThe headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
12 days ago · marketbeat.com
Adaptive Biotechnologies Q3 Earnings Call HighlightsAdaptive Biotechnologies NASDAQ: ADPT reported third-quarter net income and raised its full-year revenue outlook for its minimal residual disease business, as demand for its clonoSEQ cancer testing service increased in both clinical care and drug development.
21 days ago · seekingalpha.com
Adaptive Biotechnologies: Getting Paid Every Step Of The Way To A Myeloma CureAdaptive Biotechnologies benefits from new NCCN guidelines and IMS cure definitions, positioning clonoSEQ as the standard for long-term myeloma MRD monitoring. MRD revenues grew 33% year-over-year to $66.2M, with clinical ASP up 7% and test volumes up 43%, driving adjusted EBITDA margin to 14%. Elimination of the OrbiMed revenue share and a $345M zero-coupon note refinancing provide ADPT with over five years of runway and remove a major growth tax.
1 month ago · globenewswire.com
Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026SEATTLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2026 after market close on Wednesday, November 4, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
1 month ago · gurufocus.com
Adaptive Biotechnologies Corp (ADPT) Stock Down 3.5% but Still Overvalued -- GF Score: 68/100On October 12, 2026, Adaptive Biotechnologies Corp (ADPT) shares fell 3.5%, currently trading at $25.57. The stock has seen significant volatility, with a 52-we
2 months ago · globenewswire.com
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of CureSEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today highlighted the new consensus definition of cure for multiple myeloma, presented at the International Myeloma Society (IMS) 23rd Annual Meeting in Glasgow, Scotland, on behalf of IMS and the International Myeloma Working Group (IMWG).
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ADPT